Regeneration of T cells from human-induced pluripotent stem cells for CAR-T cell medicated immunotherapy

Background: Chimeric antigen receptor (CAR) T cell treatment involves in vitro production of T cells from patient blood with synthetic receptors specific to a cancer antigen. They circumvent the major histocompatibility complex to recognize the tumor antigen, reducing hematologic malignancy remissio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yanyan, Huang, Pufeng, Niu, Mengda, Tian, Chuanhuizi, Zhang, Tingting, Peng, Zhiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233047/
https://www.ncbi.nlm.nih.gov/pubmed/37274170
http://dx.doi.org/10.3389/fbioe.2023.1159507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233047/
https://www.ncbi.nlm.nih.gov/pubmed/37274170
http://dx.doi.org/10.3389/fbioe.2023.1159507

Ejemplares similares